These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of the inflammasome in myeloid malignancies. Chakraborty S; Shapiro LC; de Oliveira S; Rivera-Pena B; Verma A; Shastri A Blood Cancer J; 2021 Sep; 11(9):152. PubMed ID: 34521810 [TBL] [Abstract][Full Text] [Related]
10. Biology of the bone marrow microenvironment and myelodysplastic syndromes. Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353 [TBL] [Abstract][Full Text] [Related]
11. The inflammatory microenvironment in MDS. Yang L; Qian Y; Eksioglu E; Epling-Burnette PK; Wei S Cell Mol Life Sci; 2015 May; 72(10):1959-66. PubMed ID: 25662443 [TBL] [Abstract][Full Text] [Related]
12. Emerging biological therapies for the treatment of myelodysplastic syndromes. Zeidan AM; Stahl M; Komrokji R Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848 [TBL] [Abstract][Full Text] [Related]
13. [Recent advances in the treatment of myelodysplastic syndromes]. Gelsi-Boyer V; Vey N Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027 [TBL] [Abstract][Full Text] [Related]
14. Signal transduction inhibitors in treatment of myelodysplastic syndromes. Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999 [TBL] [Abstract][Full Text] [Related]
15. [The research update on cellular immune abnormality in myelodysplastic syndrome--review]. Xu F; Liu T Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):673-7. PubMed ID: 14706159 [TBL] [Abstract][Full Text] [Related]
16. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome. Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013 [TBL] [Abstract][Full Text] [Related]
17. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. Sloand EM; Barrett AJ Hematol Oncol Clin North Am; 2010 Apr; 24(2):331-41. PubMed ID: 20359629 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in myelodysplastic syndrome. Melchert M; List A Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967 [TBL] [Abstract][Full Text] [Related]
19. [Research advance of hematopoietic microenvironment for myelodysplastic syndromes]. Fei CM; Chang CK Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1246-50. PubMed ID: 23114158 [TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]